| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,625 | $179.13 | 38,503 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 9,605 | $272.73 | 28,898 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 2,588 | $272.73 | 26,310 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,000 | $30.63 | 34,310 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 898 | $272.73 | 33,412 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 3,662 | $272.73 | 29,750 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,000 | -- | 52,736 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,000 | -- | 14,079 |
| Dec 16, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,625 | -- | 43,875 |
| Dec 13, 2013 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 48,000 | -- | 60,736 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.